Pegcetacoplan Does Not Impact Anti-VEGF Treatment in Geographic Atrophy, With Ted Leng, MD, MS

Описание: According to a recent real-world evaluation, adding pegcetacoplan on top of anti-VEGF treatment for geographic atrophy (GA) does not interrupt anti-VEGF treatment patterns.1
Pegcetacoplan’s efficacy in GA treatment has been well documented through the phase 3 OAKS, DERBY, and GALE studies. The drug reduced the mean rate of change in GA area substantially across all 3 trials compared to projected sham – these improvements increased after multiple years of follow-up.
Now, in an interview with Modern Retina, Ted Leng, MD, MS, professor of ophthalmology and director of clinical and translational research at Stanford University School of Medicine, discusses preliminary results from his study investigating the interplay between anti-VEGF therapy and pegcetacoplan in patients with GA.
“Historically, we haven’t had much real-world data on how these dual therapies interact outside of clinical trials,” Leng said. “In our 18-month analysis, we found that about 1/3 of eyes being treated with pegcetacoplan already had a history of anti-VEGF treatment. And the most encouraging finding for retina specialists is the striking stability of both the treatment patterns and the clinical outcomes.”

Key Timestamps
00:00:01 Intro
00:00:10 Study overview
00:02:01 Deciding when to use pegcetacoplan
00:02:55 Barriers to uptake
00:04:29 Complement inhibition and anti-VEGF
00:05:44 AI-driven lesion predictors
00:07:41 Coordinating interdisciplinary care
00:08:44 Outro

#ophthalmology #retinacare #eyecare